S&P 500

5.652,73

0,38%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
04/05/2011	09:00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences in May	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/05/2011	09:00	Business Wire	Allos Therapeutics to Report First Quarter 2011 Results on May 10, 2011	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/05/2011	09:16	Marketwired	Oncology Drug Makers Positioned for Long Term Growth	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	17:48	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	13:35	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (DEFA14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	13:31	Edgar (US Regulatory)	Proxy Statement (definitive) (DEF 14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/04/2011	14:01	Zacks	Allos Therapeutics at Neutral - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/04/2011	12:20	Zacks	Cancer Study to Continue at SPPI - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/03/2011	09:00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/03/2011	08:35	Marketwired	Speculative Biotech Firms Remain Popular Takeover Targets	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/03/2011	18:27	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	18:20	Edgar (US Regulatory)	Annual Report (10-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	18:00	Business Wire	Allos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Pre...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	18:00	Business Wire	Allos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/02/2011	12:00	Business Wire	Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
14/02/2011	19:40	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/02/2011	17:37	Edgar (US Regulatory)	Statement of Ownership (SC 13G)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/01/2011	21:31	Business Wire	Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/01/2011	11:00	Business Wire	Allos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business Priorities	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/12/2010	11:00	Business Wire	Allos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/12/2010	11:00	Business Wire	Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/12/2010	18:15	Business Wire	New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/12/2010	12:00	Business Wire	Updated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/12/2010	12:00	Business Wire	Allos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/12/2010	12:00	Business Wire	New Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis Fungoides	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/12/2010	11:00	Business Wire	Allos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/11/2010	11:00	Business Wire	New FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	18:10	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	18:00	Business Wire	Allos Therapeutics Reports Third Quarter 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/10/2010	18:00	Business Wire	Allos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)